BridgeMD
The Expression of Fibroblast Activation Protein in Patients with Non-Small Cell Lung Cancer Patients
EU CTIS ID: 2025-523965-97-00
What this study is testing
1) To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the clinical assessment of patients with lymph node metastases in NSCLC 2) To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the assessment of cancer related distant metastasis in patient level in patients with primary NSCLC 3) To explore the feasibility of 18F-FAPI-74 PET/CT imaging in the assessesment of cancer related local lymph metastasis and distant metastasis in patient level in patients with recurrent NSCL.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Diagnosis: Histologically confirmed adenocarcinoma or squamous cell carcinoma. Study 1: No previous treatment (surgical, radiotherapy or medical treatment) for NSCLC. Study 2: Lobectomy or stereotactical radiotherapy or chemoradiotherapy for NSCLC. Clinical stage: Study 1: Stage I-III, Age: > 18 yo.
You likely can't join if
- - Infections: Patient must not have an uncontrolled serious infection - no other malignancies - no known history of sarcoidosis - Study 2: under six months after radiotherapy - Patient is not able to understand purpose of study - Medical conditions prohibiting whole body PET-CT
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.